文献速递心脑血管急症重症综合管理与镇静镇痛

重症监护病房内快速心室率心房颤动的管理:电子健康记录数据的二次分析

Management of Atrial Fibrillation with Rapid Ventricular Response in the Intensive Care Unit: A Secondary Analysis of Electronic Health Record Data.
PubMed 文献 · Shock · 2017-01-01
一句话结论在ICU快速心室率房颤患者中,美托洛尔失败率低于胺碘酮,且4小时内心率控制优于地尔硫䓬。

该研究基于MIMIC-III数据库进行二次分析,纳入1646例ICU内快速心室率房颤患者,比较美托洛尔(736例)、地尔硫䓬(292例)和胺碘酮(618例)的疗效。采用倾向评分加权比较药物失败率。与美托洛尔相比,胺碘酮失败率更高(OR 1.39,95%CI 1.03-1.87,P=0.03),地尔硫䓬有失败率升高趋势(OR 1.35,95%CI 0.89-2.07,P=0.16)。在单药治疗患者中,地尔硫䓬4小时内控制率低于美托洛尔(OR 0.64,95%CI 0.43-0.97,P=0.03)。初始药物与院内死亡率无关。

要点

  • 在ICU快速心室率房颤患者中,与美托洛尔相比,胺碘酮药物失败率更高(OR 1.39,95%CI 1.03-1.87,P=0.03)。
  • 与美托洛尔相比,地尔硫䓬药物失败率有升高趋势但未达统计学显著(OR 1.35,95%CI 0.89-2.07,P=0.16)。
  • 单药治疗患者中,地尔硫䓬4小时内控制率低于美托洛尔(OR 0.64,95%CI 0.43-0.97,P=0.03)。
  • 初始选择美托洛尔、地尔硫䓬或胺碘酮与院内死亡率无关。
  • 美托洛尔是该ICU中最常用的快速心室率房颤治疗药物(736/1646例)。

适用人群与场景

  • ICU首次入院患者,心率>110 bpm且临床病历记录有房颤,并接受了美托洛尔、地尔硫䓬或胺碘酮之一治疗。

诊断标准与关键阈值

  • 快速心室率房颤:心率>110 bpm且临床病历记录有房颤。

研究设计与关键结果

  • 研究类型:电子健康记录数据的二次分析,基于MIMIC-III数据库,纳入1646例ICU快速心室率房颤患者。
  • 分组:美托洛尔736例,地尔硫䓬292例,胺碘酮618例;采用广义提升模型进行倾向评分加权比较药物失败率(终止快速心室率前使用第二种药物)。
  • 主要终点:与美托洛尔相比,胺碘酮失败率更高(OR 1.39,95%CI 1.03-1.87,P=0.03);地尔硫䓬失败率有升高趋势(OR 1.35,95%CI 0.89-2.07,P=0.16)。
  • 次要终点:单药治疗患者中,地尔硫䓬4小时内控制率低于美托洛尔(OR 0.64,95%CI 0.43-0.97,P=0.03)。
  • 初始药物与院内死亡率无关。

证据类型、等级与局限

  • 证据类型:基于电子健康记录数据的二次分析(观察性研究)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 在ICU快速心室率房颤患者中,作者结论认为美托洛尔失败率低于胺碘酮,且在4小时心率控制方面优于地尔硫䓬。
  • 原文未据此给出推荐。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

PURPOSE: Atrial fibrillation with rapid ventricular response (RVR) is common during critical illness. In this study, we explore the comparative effectiveness of three commonly used drugs (metoprolol, diltiazem, and amiodarone) in the management of atrial fibrillation with RVR in the intensive care unit (ICU).

METHODS: Data pertaining to the first ICU admission were extracted from the Medical Information Mart for Intensive Care III database. Patients who received one of the above pharmacologic agents while their heart rate was > 110 bpm and had atrial fibrillation documented in the clinical chart were included. Propensity score weighting using a generalized boosted model was used to compare medication failure rates (second agent prior to termination of RVR). Secondary outcomes included time to control, control within 4 h, and mortality.

RESULTS: One thousand six hundred forty-six patients were included: 736 received metoprolol, 292 received diltiazem, and 618 received amiodarone. Compared with those who received metoprolol, failure rates were higher amongst those who received amiodarone (OR 1.39, 95% CI 1.03-1.87, P = 0.03) and there was a trend towards increased failure rates in patients who received diltiazem (OR 1.35, CI 0.89-2.07, P = 0.16). Amongst patients who received a single agent, patients who received diltiazem were less likely to be controlled at 4-h than those who received metoprolol (OR 0.64, CI 0.43-097, P = 0.03). Initial agent was not associated with in-hospital mortality.

CONCLUSIONS: In this study, metoprolol was the most commonly used agent for atrial fibrillation with RVR. Metoprolol had a lower failure rate than amiodarone and was superior to diltiazem in achieving rate control at 4 h.

来源:Shock,查看原文。版权归原作者所有。

参考来源

  1. Moskowitz A, Chen KP, Cooper AZ, et al. Management of Atrial Fibrillation with Rapid Ventricular Response in the Intensive Care Unit: A Secondary Analysis of Electronic Health Record Data. Shock. 2017. PMID: 28328711. doi:10.1097/SHK.0000000000000869

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。